公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2011 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH ; Thongprasert S.; Lu S.; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 35 | 36 | |
2015 | Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy | Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU ; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. | Clinical Cancer Research | 408 | 382 | |
2017 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival | Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU ; Gralla R.J.; Gebski V.; Mok T.; CHIH-HSIN YANG | Journal of the National Cancer Institute | 204 | 171 | |
2013 | Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial | Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU ; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T. | The Lancet Oncology | 277 | 247 | |
2016 | The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients | Thongprasert S.; PAN-CHYR YANG ; Lee J.S.; Soo R.; Gruselle O.; Myo A.; Louahed J.; Lehmann F.F.; Brichard V.G.; Coche T. | Lung Cancer | 17 | 17 | |
2014 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) | Shi Y.; Au J.S.-K.; Thongprasert S.; Srinivasan S.; Tsai C.-M.; Khoa M.T.; Heeroma K.; Itoh Y.; Cornelio G.; PAN-CHYR YANG | Journal of Thoracic Oncology | 1087 | 977 | |
2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 71 | 68 | |
2016 | Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer | Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU ; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L. | Lung Cancer | 20 | 18 |